Health
Novel breast cancer therapy candidate enters clinical study – Mirage News
Kiran Dhillon In a UW Medicine cancer immunotherapy lab, research scientist Nick Drovetto puts a rack of samples into a liquid nitrogen tank. A Phase 1…
A Phase 1 patient trial of the novel, oral therapy candidate, Alpha TEA, for advanced HER2 positive breast cancer is now underway. Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin.
In HER2 positive breast cancer, the tumor cells produce a higher-than-usual level of the HER2protein that drives cancer growth and spread.
Alpha TEA lysine…
-
General7 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General23 hours agoParis opens River Seine for public swimming for first time since 1923
-
General22 hours agoWest Indies vs Australia live: Second Test, day three from Grenada
-
General21 hours agoDr Daniel Hunt, Michael Long and Christine Anu celebrated at 50th NAIDOC Week Awards